Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry (2022) Laakmann E, Riecke K, Neunhoeffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, et al. Conference contribution Breast volume assessment with a smart phone device compared to MRI (2022) Behrens A, Wunderle M, Häberle L, Stamminger M, Zint D, Emons J, Heindl F, et al. Conference contribution Methodological Establishment of an in-vitro ADCC Assay by using patient-specific Immune Cells (2022) Lehle S, Völkl S, Rübner M, Emons J, Seitz K, Beckmann M, Fasching P, Hübner H Conference contribution, Conference Contribution Smart sensing in pregnancy: a survey-based evaluation of readiness to use wearable sensory applications in prenatal care (2022) Weidenthaler F, Danzberger N, Pontones C, Titzmann A, Hein A, Beckmann M, Fasching P, Huebner H Conference contribution Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus (2022) Untch M, Fasching P, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, et al. Journal article, Review article AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) Banys-Paluchowski M, Thill M, Kuhn T, Ditsch N, Heil J, Woeckel A, Fallenberg E, et al. Journal article HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies (2022) Haegele M, Mueller KR, Denkert C, Schneeweiss A, Sinn BV, Untch M, Van Mackelenbergh MT, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis (2022) Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, et al. Conference contribution